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Abstract 
The incidence of breast cancer in developing countries showed an increase from year to 
year. The efforts of cancer prevention or treatment of the more important given the 
frequency of occurrence is quite high. Several studies have been focuses on natural 
products as agents of cancer chemoprevention and as co-chemotherapy agent against 
cancer. One of medicinal plant that is widely used as anticancer is rodent tuber 
(Thyphonium flagelliforme (Lodd.) Blume). In present study, we investigated the 
anticancer acitivty of rodent tuber extract (RTE) in vitro. Study of anti-proliferative 
conducted on human breast cancer primary T47D cells. Furthermore, the present study 
also investigated the molecular mechanisms of cell cycle arrest and induction of 
apoptosis. The study of rodent tuber as co-chemotherapy is determined by examining 
the effects on T47D and its combination with tamoxifen (TAM). The results showed 
the cytotoxic effects of RTE on T47D cells with IC50 value of 632 μg/mL. Low 
concentration RTE (below 250 ug/mL) are proliferative, while the concentration above 
250 μg/mL indicated cytotoxic effect. Based on the calculation of Combination Index 
(CI), combination of RTE with TAM yielded a value above 10 indicated a strong 
antagonistic effect. In observation of apoptosis, low concentration of RTE (63 µg/mL) 
stimulate apoptosis better than high concentration of 250 μg/mL. However, the 
combination study with 5 nM TAM reduced the induction of apoptosis. Furthermore, 
the observation cell cycle arrest by flowcytometry, demonstrated that RTE 63 and 250 
μg/mL increase the population of sub G1 phase respectively from 14.8% to 53.19 and 
32.90%. These results suggest that RTE able to induce cell cycle to apoptosis, but low 
concentration of RTE more effective than high concentration. Similar to apoptosis 
observation, the combination of RTE and TAM also demonstrated the antagonistic 
effect by reducing the population of Sub-G1 RTE (63 μg/mL) and TAM 5 nM, 
respectively from 53.19% and 44.50% to 35.86%. All finding results of this study 
provide information that the use of rodent tuber extract (RTE) alone is better than the 
combination with TAM. In addition, the use of RTE together with TAM reduced the 
effectiveness of TAM in the treatment of breast cancer. 
Keywords: Rodent tuber (Thyphonium flagelliforme (Lodd.) Blume), anti cancer, 
chemoprevention, T47D cells. 
Introduction 
Breast cancer (BRCA) is the cancer with high 
prevalence and the second cause mortality 
women in USA (American Cancer Society, 
2005). The incidence of breast cancer in 
development country also indicated increase 
every year [1-2]. National Cancer Institute USA 
in 2005 reported that the percentage of breast 
cancer patient is the highest rank in the world 
(24.2%). Due to the frequency of occurrence is 
quite high, many efforts was done to find the  
 
agent for prevent or treatment breast cancer. 
Several studies focus to explore the potential of 
natural products as agents for prevent or 
treatment breast cancer.  
One of the medicinal plant that is widely used as 
anticancer is rodent tuber (Thyphonium 
flagelliforme (Lodd.) Blume. Rodent tuber 
rounded average like a nutmeg. The inside and 
outside is white bulb. Its can use the tubers or 
seedlings that grow from tubers for breeding. In 
the dry season, the trunk disappeared while in the 
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rainy season, these plants appeared again on the 
surface of the soil tubers are buried in the ground. 
The crown-shaped flowers are small, white long 
tail similar to rats. But there are some types that 
have a red-colored petals. This type of rodent 
tuber are usually use and grow for hybrid plants. 
Rodent tuber has been widely used to treat many 
type of cancer especially breast cancer. Previous 
study has shown that hexane fraction of rodent 
tuber are cytotoxic against P388 murine leukemia 
(IC50 ∼ 15 μg/mL) [3]. Some fraction of hexane 
and dichloromethane were reported capable to 
inhibit the growth of NCI-H23 lung cancer 
significantly, with IC50 <15 μg/mL and found 
that the fraction D/F21 was an active fraction for 
the inhibition of cancer growth [4]. Other study 
found four pheophorbide compounds and 
fractions D/F19 of rodent tuber that are anti-
proliferation against cancer cells [4]. The study 
on rodent tuber as an anti cancer has not been 
much done, although its use as an anti cancer 
already quite extensive, especially in Indonesia 
and Malaysia as a product of traditional medicine 
or herbal medicine. 
 
Based on the above reasons, it is important to 
explore and study in deep of rodent tuber as 
herbal medicine includes mechanisms of action 
or as co-chemotherapy for cancer treatment. 
Scientific proven of rodent tuber as anti-cancer 
drug is needed to ensure public that herbal 
medicine of rodent tuber is scientifically proven 
as an anti-cancer. This study also used as a basis 
for the development of herbal medicine in vivo 
as well as clinic. 
 
Materials and Methods 
Materials  
Rodent tuber (Thyphonium flagelliforme (Lodd.) 
Blume) was obtained from the Garden of 
Medicinal Plant Development (CV. Merapi 
Farma, Yogyakarta, Indonesia). Human breast 
carcinoma cells used in this study is the T47D 
cell that was obtained from Prof. Tatsuo Takea 
(Nara Institute Sciences and Technology, Japan). 
Tamoxifen was obtained from Sigma Co.. Chem. 
T47D cells were grown with RPMI medium 
containing 10% FBS (Gibco), penicillin-
streptomycin 1% (GIBCO), and fungizon 0.5% 
(GIBCO). Cells culture were growth and incubate 
in CO2 incubator. Material for the proliferation 
assay were [3 - (4,5-dimetilthiazol-2-yl) -2.5-
diphenyl tetrazolium bromide] (MTT) (Sigma 
Chemical, St Loius, MO), H2O2 (Lab Vision 
Plus), chromogen 3,3-diaminobenzidin (DAB) 
(Novo Castra) were used in this study. Other 
materials are pharmaceutical and biochemical 
grade. 
 
Preparation of rodent tuber extract (RTE) 
Rodent tuber sliced into small size and dried in an 
oven 60° C, after dried in powder, then sieved to 
obtain dry powder. A total of 500 grams of 
powder were macerated with 96% ethanol for 5 
days. Ethanol fraction obtained was concentrated 
by rotary vacuum evaporator to obtain viscous 
extract. The existence of the remaining traces of 
water was dried by freeze drying. 
 
Cell proliferation assay 
Cell viability was determined by the MTT 
colorimetric assay (3-[4,5-diethylthiazol-2-yl]-
2,5-dipheniltetrazolium bromide (Sigma St. 
Louis, MO, U.S.A.). After cells reached 80% 
confluently and good viability, the cells were 
seeded at a concentration of 5 x 103 cells/well 
(MCF-7) and 1.0 x 104 cells/well in 96- well 
plates (Becton Dickinson Co., NJ, USA) and 
cultured in appropriate medium at 37 °C in a 5% 
CO2 atmosphere. After 48 h of attachment, 
culture medium was discarded and the cells were 
treated with various concentrations of rodent 
tuber exctract (RT) (0, 10, 25, 50, 100, 250, 500, 
1000 μg/mL) and 1, 10, 20, 30, 40, 50, 60 nM 
(tamoxifen) in 100 μl serum-free and phenol red-
free DMEM or RPMI. T47D cells were treated 
for 48 h. After treatment, cells were incubated 
with 10 μl of MTT (5 mg/mL) for 6 h at 37°C. 
After 6 h, add the stopper 10 % SDS (Sigma Co., 
St.louis, MO) in 0.01 N HCl (Merck) in incubate 
for 24 hours in room temperature. After 24 h 
incubation, measured cells absorbance by 
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spectrophotometric using ELISA reader (λ 550 
nm).  
 
Co-chemotherapy assay 
T47D cells were distributed in 96 well plate with 
the number 5.0 × 103 cells per wells and 
incubated with test samples (RT extracts and 
tamoxifen as a single compound) with a series of 
levels 1/8, 1/4, 1/3; ½ IC50 (RT extract ) and 1/10, 
1/5, 1/2, 3/5 IC50 (tamoxifen) and also 
combination of tamoxifen and of RT extracts. 
Then followed such an experiment like cells 
proliferation assay above. Synergistic 
cytotoxicity determined by calculating the 
interaction index (CI = Combination Index) 
between the agent chemotherapy with rodent 
tuber extract (Thyphonium flagelliforme (Lodd.) 
Blume, using the equation: 
 
I = (D)1 /(Dx)1 + (D)2 / (Dx)2 
 
Where Dx is the concentration of a single 
compound required to give effect (in this case is 
the IC50 against breast cancer cell growth) and 
(D)1, (D)2 is the concentration of both compounds 
to give the same effect (Notarbartolo et al ., 
2005). Based on the value of I obtained 
(synergistic cytotoxicity) can be interpreted: 
<0.1: very strong synergistic; 0.1-0.3: strong 
synergistic; 0.3-0.7: moderate synergistic; 0.7-
0.9: synergistic; 0.9-1.1: almost additive; 1.1-
1.45: moderate antagonist; 1.45-3.3: antagonist; > 
3.3: very strong antagonist. 
 
Apoptosis observation 
T47D cells were grown on coverslips which 
placed in the microplate 24 wells in order to 
obtain the density of 3 X 104 cells /wells and 
incubated until 50-60% confluent. After that it 
was incubated with RT extracts for 48 hours. 
Medium was removed, then washed with PBS. 
Coverslips containing the cells is removed, put on 
the object glass and add 10 mL 1X Working 
Solution acridin orange-ethidium bromide and 
then allowed to stand for 5 minutes. Cells 
immediately observed under the microscope 
fluorescence (Zeiss MC80). Green fluorescence 
indicated the life cells (with acridin orange) and 
orange fluorescence indicated the apoptosis cells 
with ethidium bromide. 
 
Cell cycle analysis 
T47D cells were seeded in complete medium (5 × 
105 per 60-mm plate). After 24 h, cells were 
incubated in an incubator overnight to 
synchronize them in G2/M phase. Then samples 
were washed and placed in complete medium 
with DMSO (control), RT extract (63 and 250 
μg/mL) or tamoxifen (TAM) (5 nM) for 24 and 
48 h to assess the effects on cell cycle 
progression. Both floating and adherent cells 
were collected, washed twice with cold PBS and 
centrifuged. The pellet was fixed in 70% ethanol 
in PBS at 4°C for 1 h, washed twice with cold 
PBS and then resuspended in PBS containing 40 
μg/ml PI and 100 μg/ml RNAse, at 37°C for 30 
min. Samples were then analyzed on the 
FACScan flowcytometer. After activation of the 
'doublet discrimination module' and exclusion of 
cell debris defining a gate in the side and forward 
scatter dot-plot, at least 10 000 events per sample 
were acquired in linear mode. Percentage of cells 
in subG1, G1, S and G2/M phases were 
calculated using the CellQuest software (Becton 
Dickinson). 
 
Statistical Analysis 
Data from the in vitro experiments were 
expressed as the mean ± S.E.M. The statistical 
significance of differences between the groups 
were assessed with a one-way ANOVA, followed 
by Bonferroni or LSD post-hoc test analysis 
using rel 13.0 software SPSS (Chicago, IL, 
USA). p values of less than 0.05 were considered 
to indicate significant differences. 
 
Results and Discussion 
Cell proliferation assay 
In this study, rodent tuber extracted using ethanol 
that can extract both polar and semipolar 
compounds in the rodent tuber. The extractive 
value of ethanol from dried powders of rodent 
tuber (Thyphonium flagelliforme (Lodd.) Blume 
was calculated as % w/w yield and was found to 
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be 10.71%. Cell proliferation assay of rodent 
tuber (RT) extract performed on T47D cells as a 
model of primary human breast cells. The 
concentrations of extract used were 10, 25, 50, 
100, 250, 500, and 1000 ug/mL. The results 
demonstrated that the extract in the range 
concentration of 10-250 μg/mL showed a 
tendency to T47D cell proliferation, whereas 
increasing concentrations of extract more than 
250 ug/mL showed inhibitory or cytotoxic effect 
on T47D cells. Biphasic effect of these study 
showed that the extract induced cells proliferation 
at levels less than 250 ug/mL and inhibition of 
cells proliferation or cytotoxic for concentrations 
above 250 ug/mL. It is likely there are 
compounds in the extracts that are estrogenic 
such like phytoestrogens.  
 
 
Figure 1. Effect of rodent tuber extract (RTE) on T47D 
cells viability. Experiments were conducted with an 
incubation time of 48 hours. Data represent mean ± SD of 
triplicate. 
 
The results are consistent with previous studies 
that phytoestrogens such as genistein could 
inhibit the growth of cancer cells in vitro include 
hormone-dependent breast cancer or not with the 
IC50 ranged between 10-50 μmol/L [5-8]. While 
at concentrations <10 μmol/L, the growth of 
MCF-7 (estrogen receptor-positive cell line) 
stimulated by genistein [7,9,10]. The calculation 
result using semilog linear regression of 
concentration versus cell viability (%) obtained 
the equation y = 121.40x-0,113. The calculation 
result obtained IC50 value of RT extract 632 
μg/mL (Figure 1). Mechanism of cytotoxic or cell 
proliferation possibility could be through 
inhibition of one or more cellular molecules that 
control cell signaling, cell growth and apoptosis. 
The IC50 of RT extract on cell inhibition of T47D 
human carcinoma cells showed a low value that 
is equal to 632 μg/mL. This result indicated that 
the active compound in rodent tuber extract small 
and needed purified to get greater anti cancer 
activity.  
 
 
Figure 2. Effect of TAM on T47D cells viability. 
Experiments were conducted with an incubation time of 48 
hours. Data represent mean ± SD of triplicate. 
 
Furthermore, treatment of tamoxifen (TAM) as 
one of SERMs showed very effective against 
cancer cells T47D (Figure 2). Tamoxifen is a 
drug that is often used for the treatment of breast 
cancer as in research International Breast Cancer 
Intervention Study-1 [11], Royal Marsden 
Hospital [12], and Italian [13], that women who 
receive tamoxifen women randomly shows 36% 
reduction in the incidence of ductal carcinoma-in-
situ (DCIS) and 46% reduction on the incidence 
of invasive breast cancer [14]. In this study, TAM 
administration very effectively inhibits the 
growth of T47D cells with very low 
concentrations in the range 1-60 nM. Results of 
linear regression calculations indicate the value 
of IC50 was 27.48 nM. T47D cells are ER-positive 
breast cancer as evidenced by the response to 
increased proliferation as a result of exposure to 
17-estradiol [15]. Tamoxifen (TAM) is one of the 
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estrogen antagonist which inhibits the activity of 
estrogen in most tissues that are sensitive to 
estrogen. TAM has become the standard 
treatment for all stages of breast cancer in both 
pre-menopausal women and post-menopausal 
[16]. The potential benefits of the use of TAM as 
a precaution has been widely studied, in addition 
reported that TAM can reduce the risk of breast 
cancer approximately 50% of most women who 
have a high risk of breast cancer [17]. These 
results of TAM on cell proliferation assay were 
supported by previous studies. 
 
 
Figure 3. The combination study of tamoxifen (TAM) and 
rodent tuber extract (RT) on the percentage of cells 
viability of T47D and combination index (CI) using MTT 
method. Graph indicated relationship the combination of 
RTE and TAM on the T47D cells viability (A), and the 
combination index (B). Data are mean ± SD of 3 
replications. Experiments conducted with an incubation 
time of 48 hours. 
  
Co-chemotherapy assay 
Further study carried out co-chemotherapy to 
know the efficacy of tamoxifen as the standard 
treatment of breast cancer. Combination study 
treatment made by combining tamoxifen (TAM) 
with RTE. The concentrations of TAM and RTE 
used in this study were 2.75, 3.44, 6.875, 10.3 
(TAM) and 63.2; 79; 158, 237 (RTE). Figure 3 
described the effect of combination of extracts 
RTE-TAM. The potential combination of 
tamoxifen with RTE is determined by the 
combination index (CI). Almost all treatment 
combinations of tamoxifen with RTE is a 
combination that gives a very strong antagonistic 
effect (CI> 3.3), indicated a decreased effect 
exceeds the sum of the effect produced when a 
single administration. From the results of RTE-
TAM combination can be inform that 
administration of combination would reduce the 
effectiveness of extract or TAM as anti cancer. 
The use of RTE as co-chemotherapy is not 
effective to increase the efficacy of tamoxifen for 
treatment in patients with breast cancer. 
 
Apoptosis observation 
In this study, apoptosis observation carried out by 
double stainning method using ethidium 
bromide-acrydine orange. Observations showed 
that in control cells visible only green 
fluorescence due to just absorb acrydine orange. 
Ethidium bromide can not penetrate the cell 
because it controls cell integrity is still good. In 
cells treated with RTE (63 μg/mL) largely cells 
seen as green fluoresence and some orange. This 
orange fluroesence indicated that RT extract 
capable to induce apoptosis. It is can be 
understand that treatment of RTE (63 μg/mL) 
shown only a small fraction of cells indicated 
orange fluoresence because the concentration are 
still below IC50. Increased concentration of RTE 
to 250 μg/mL, further increase induction of 
apoptosis which is marked by the increasing 
number of cells seen as orange fluorescence. This 
shows that the treatment of RTE can induce 
apoptosis (Figure 4). In contrast, RTE and TAM 
combination were reduce the number of cells 
undergoing apoptosis (Fig. 4B-E, and CF). All of 
the observation of apoptosis showed that the 
combination of RT with TAM is less effective in 
promoting apoptosis than the single 
administration of RTE. In addition, the use of RT 
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and TAM will simultaneously reduce the 
effectiveness of tamoxifen in promoting cancer 
cell induce apoptosis. 
 
 
Figure 4. The effect of RTE and its combination with TAM 
on apoptosis induction in T47D cells after 48 hours of 
administration. Staining was done by grown T47D cells (5 
× 104 cells/well on coverslips in the plate 24, carried 
acrydine staining using ethidium bromide-orange and 
viewed with a microscope fluorosence. (A) control cells, 
(B) RTE 63 μg/mL, (C) RTE 250 μg/mL, (D) TAM 5 nM, 
(E) RTE 63 μg/mL and TAM 5 nM and (F) RTE 250 
μg/mL and TAM 5 nM. 100x magnification.  
         : apoptosis cells;          : life cells 
 
Cell cycle arrest 
Furthermore, we also observe and evaluate the 
effects of RTE and their combinations on cell 
cycle profiles using flow cytometry as shown in 
Figure 5. As shown in Figure 5, administration of 
RTE (63 and 250 μg/mL) increased the 
population of sub G1 phase respectively from 
8.14 to 53.19 and 32.90%. These results show 
that rodent tuber extract (RTE) was able to 
induce cell cycle to apoptosis, but low 
concentration of RTE induced apoptosis more 
effective than high concentration. The 
combination of RTE and TAM demonstrated the 
antagonistic effect to reduce the population of 
Sub-G1 RTE (63 μg/mL) and TAM (5 nM) of 
53.19% and 44.50%, respectively to 35.86% 
(Figure 5). The results are consistent with 
previous observations of both apoptosis and the 
combination index calculations showed that the 
combination of RTE and TAM is antagonistic 
effect. The results that not dose-dependent likely 
indicate a proliferative compounds that are at 
such low consentration of phytoestrogens. On the 
other hand, the possibility of high concentration 
of RTE, there are any DNA repair mechanisms 
that can pass through G0 phase. These results 
provide information that the use of RTE as a 
single administration is better than the 
combination. In addition, the use of extracts of 
RTE together with TAM actually reduced the 
effectiveness of TAM in the treatment of breast 
cancer. All the observation of cell cycle arrest, 
RTE capable to induce apotosis on T47D cells, 
but the molecular signaling study is needed on 
specific protein cyclin, such as CDK4 and CDK6 
involved in G1 progression, and a variety of CDK 
inhibitors that may occur for the regulation of the 
cell. 
 
In conclusions, this study demonstrated that RTE 
capable to inhibit cell proliferation of T47D cells. 
The combination of RTE with tamoxifen was 
resulted an antagonistic effect. In the observation 
of apoptosis and cell cycle arrest can be seen that 
administration of single rodent tuber extract low 
concentration induced apoptosis effectively than 
high concentration or its combination with TAM. 
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Figure 5. Distribution of Cell Cycle T47D cells using flow cytometry after staining with propidium iodide (PI). (A) Control 
cells; (B) treatment of RTE 63μg/mL; (C) treatment of 250 μg/mL; (D) TAM 5 nM; (E) combination of RTE 63 μg/mL and 
TAM 5 nM; (F) combination of RTE 250 μg/mL and TAM 5 nM. I: Sub-G1; II: G0/G1; III: S; IV: G2/M. All treatment is a 
representation of 20,000 cells and the percentage of cells in cell cycle phase is indicated beside each cell cycle distribution. 
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